Feedback Share Discussion Threads

[petekand] 30/11/2018 12:11

Revamp the website? Yes I am stil having to deal with the annoying pop up I reported previously. Deleted all cookies and website data but it still shows making the site almost unusable. LR2 thought I may have clicked on something in error but there is no log in button anywhere that I could have clicked.

[ged5] 30/11/2018 10:50

When was the process started for FDA approval of TexRAD?

[ged5] 30/11/2018 10:48

Good reminder ducatiman!

Earlier question:-

Given the connection with Samsung, have Samsung incorporated TexRAD in their diagnostic imaging equipment?

Repeat of link given in previous post.

[ducatiman] 30/11/2018 10:41

Tim, could you ask if Siemens are bundling texrad into their scanners as reported on another website.

[ged5] 30/11/2018 10:24

Well done Tim!

Immediate question is Could they please revamp the website?

How big is the market they are targeting for both TexRAD and CADRAN?

Are they just going to focus on the 3 products TexRAD research, TexRAD lung and CADRAN?

Which other areas do they see TexRAD as commercially viable?

Do they have anyone monitoring the Contact Us link on the website?

Do they ever answer questions from PIs?

[ducatiman] 30/11/2018 10:12

Thank you Tim. It is good to see that they are happy to meet with a PI. I am actually extremely happy with the way the company is being managed currently but if I think of a specific question I would like an answer to I will give you a shout.

[tim000] 30/11/2018 09:52

I've arranged a meeting with Alasdair Riddell in early December. If there are any questions you'd like me to ask him, bearing in mind market sensitivities, please let me know. Thanks.

[lr2] 29/11/2018 21:29

Had a nice slow read of the accounts. I'm happy.

[ducatiman] 29/11/2018 21:20

Gym, never been so excited about a company's potential, outside of the oil and gas sector, lol.

[gymratt] 29/11/2018 20:50

Lots to look forward to, Duc... and look at that chart; signs of a 'bowl' starting to take shape(AIMMHO!).. :0)

[ducatiman] 29/11/2018 20:43

I also liked this!! LR2 has been wondering what has been happening on this front. Here is the answer.


"Discussions with Alliance Medical for integrating TexRAD® Lung into its network of PET/CT scanners in UK hospitals continue. The Company recognises that there has been little announced progress on these discussions, but with the assistance of new Medical Director, Prof Rory Shaw, the Board believes that the improved company structure will result in progress on these discussions in the near term."

[ducatiman] 29/11/2018 20:38

I liked this:-

"It is undergoing clinical evaluation in pilot installations within three UK hospitals and the results of these pilots will inform the next stage of maximising this important technology for clinical use"

[ged5] 29/11/2018 16:13

A very professional, well written set of results.

Nice to see it is a going concern over the next 12 months and although all the risks have been highlighted the directors are loaded with significant amount of shares. Make of that, what you will!

The statement about new applications for Texrad is very pertinent this week. I have read the abstracts from this weeks presentations and apart from the first one the conclusions are that Texrad will be useful in each of the areas, some of which are the scourge of mankind. Early days for those applications but they will eventually add to the pipeline.

As you say ducatiman, plenty of excellent reading.

[ducatiman] 29/11/2018 15:12

Wow, loads of excellent reading in there. Very exciting times ahead!!

[petekand] 29/11/2018 15:03

""As the role of AI in assisting medical management decisions begins to be appreciated, our products sit at the heart of this, assisting radiologists to analyse and assess digital images from CT, MRI and PET scans. The existing broad international customer base for our TexRAD(R) research product will form the springboard for the clinical product following regulatory approval and validation in clinical trials."

Big springboard built and we are at the heart! I am going nowhere for the next few years and I believe big rewards await.

[lr2] 29/11/2018 14:46

Final Results.

[tim000] 28/11/2018 11:48

I would guess Friday. Obviously the interest will be in invoices secured in the current FY. They won't have any figures yet for Q2 FY19 (assuming results are announced this week), but they should be able to provide an update since the previous Trading Update, which covered Q1. And maybe something on Cadran. Personally I'm not expecting anything so significant that it will move the share price, I'm expecting next year to be more interesting. But you never know...

[ducatiman] 28/11/2018 11:12

Results can't be far off. Hopefully some positives with them. A bit quiet at the moment.

[ged5] 26/11/2018 15:28

ok, thanks.

With 4 presentations today lets hope texture analysis proves to be more useful.

[lr2] 26/11/2018 15:01

Difficult to say for certain Ged. However Samsung are a Korean company and TexRAD is being used by Korean researchers at RSNA.

SSA14-02 Application of Texture Analysis in the Differential Diagnosis of Osteoblastic Metastases and Enostoses: Comparison with CT Attenuation Measurements

Sunday, Nov. 25 10:55AM - 11:05AM Room: E353C

Participants
Seong Woo Jeon, MD, Suwon, Korea, Republic Of (Presenter) Nothing to Disclose
Kyu-Sung Kwack, MD, PhD, Suwon, Korea, Republic Of (Abstract Co-Author) Nothing to Disclose
Sunghoon Park, MD, Suwon, Korea, Republic Of (Abstract Co-Author) Nothing to Disclose

PURPOSE
The purpose of this study was to investigate the role of CT texture in distinguishing between osteoblastic metastases from enostoses and to compare the results with CT attenuation values.

METHOD AND MATERIALS
The study group comprised 32 patients with 64 sclerotic bone lesions found at CT (41 enostoses in 24 patients and 23 metastases in 8 patients). For each lesions in spine, CT texture analysis was performed by drawing a region of interest on axial CT slices. The histogram parameters (mean, SD, kurtosis, entropy, and skewness) were acquired using a research software 'TexRAD'. The diagnostic performances of mean CT attenuation values and texture analysis for differentiating osteoblastic metastases from enostoses were evaluated.

RESULTS
Mean CT attenuation values had the best diagnostic performance with an ROC AUC (Az) of 0.953 among all parameters. Among CT texture analysis parameters to differentiate osteoblastic metastases and enostoses, the kurtosis had the highest ROC (Az = 0.787) than the entrophy (Az = 0.763) and skewness (Az = 0.691). The combination of mean attenuation and CT texture analysis parameters had poorer performance than mean CT attenuation values alone.

CONCLUSION
Using texture analysis does not improve diagnostic performance in the differentiation of osteoblastic metastases and enostoses in
the spine.

CLINICAL RELEVANCE/APPLICATION
CT texture analysis may have a spectrum of potential application in lesion characterization for some tumor types. However, based on our data, we cannot recommend adding CT texture analysis to differentiate osteoblastic metastases of the spine.

- see page 84.

[tim000] 25/11/2018 20:33

Duc, your point about widening our market with new applications is well made. I live fairly close to HQ and after the FY results are announced, I plan to make contact with the company to see if they are willing to meet up with PIs. If they are, that will be something I wish to explore. BTW, I wouldn't expect any tip sheet coverage until the mkt cap is significantly higher, as there won't be the liquidity in the market to absorb a large number of orders.

[ducatiman] 25/11/2018 19:35

Not much gets past him Gym. Would I be correct in saying that all negatives should now be behind us and we patiently await the positives?
Also, We are a medical imaging company and obviously that is the market but could this texture analysis breakthrough have applications outside of the medical arena?

[gymratt] 25/11/2018 16:34

LR ~ Leading Research

;0)